Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › PEX168 add-on to metformin phase 3b

PEX168 add-on to metformin phase 3b

PEG-loxenatide · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
PEG-loxenatide
Population
t2d
Phase
3
Duration
24 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
100 μg + metformint2d china24———−1.2————0.0 vs 0.0—press release
200 μg + metformint2d china24———−1.1————0.0 vs 0.0—press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (4)
  • 100 μg + metformin · hba1c · publication
    in the PEX168 groups (-1.16% [0.08%] and -1.14% [0.08%] with 100 and 200 μg, respectively)
  • 100 μg + metformin · sae · Abstract, Results
    No treatment-emergent serious adverse events occurred.
  • 200 μg + metformin · hba1c · publication
    in the PEX168 groups (-1.16% [0.08%] and -1.14% [0.08%] with 100 and 200 μg, respectively)
  • 200 μg + metformin · sae · Abstract, Results
    No treatment-emergent serious adverse events occurred.

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: PEX168 add-on to metformin phase 3b. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/pex168-add-on-to-metformin-phase-3b/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.